PHYSICAL, EMOTIONAL AND SOCIAL STRESSORS AND THEIR IMPACT ON QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PATIENTS WITH CANCER
My Fellowship project was on characterizing caregivers of older adults with cancer admitted to hospital and understanding potential physical, social and psychological stressors affecting them.
I did my Fellowship at City of Hope Comprehensive Cancer Centre in Duarte California USA under the mentorship of Dr. Arti Hurria.
This Fellowship was critical in helping me develop the research skills, as well as contacts within the field of geriatric oncology, that I continue to cultivate today. It has lead to a variety of research collaborations, but also invitations to be a part of international committees and panels and undoubtedly played a large part in being invited to speak at international conferences.
I am staff physician medical oncologist in Ottawa.
Tina Hsu, MD1; Matthew Loscalzo, LCSW2; Rupal Ramani, BS1; Stephen Forman, MD3; Leslie Popplewell, MD3; Karen Clark, MS4; Vani Katheria, MS1; Tao Feng, MS1; Rex Strowbridge, AA5,6; Redmond Rinehart, BS5; Dan Smith5; Keith Matthews, AS5; Jeff Dillehunt, AS5; and Arti Hurria, MD1 “Factors Associated With High Burden in Caregivers of Older Adults With Cancer” Cancer 2014;120:2927-35. VC 2014.
A PHASE II TRIAL COMPARING LOW DOSE METRONOMIC CYCLOPHOSPHAMIDE AND CEDIRANIB TO CYCLOPHOSPHAMIDE AND PLACEBO AS MAINTENANCE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
My initial project was a phase II trial of an angiogenesis inhibitor in the treatment of metastatic colon cancer, but unfortunately the study did not end up being funded, although I did learn a great deal regarding the design of phase II clinical trials. I subsequently completed and published a cost-effectiveness analysis dealing with treatments for metastatic pancreatic cancer and a national study examining oncology education in undergraduate and postgraduate family medicine and internal medicine programs in Canada.
Sunnybrook Odette Cancer Centre, Toronto
My Fellowship training was in GI Medical Oncology, phase II trials and oncology education. I have put this training to good use and am currently treating GI cancers, extensively involved in undergraduate medical education (teaching and curriculum design) and am the local principal investigator for a number of phase II and III hepatobiliary cancer trials.
I am a staff medical oncologist at the Tom Baker Cancer Centre / University of Calgary
PHASE IB STUDY OF SORAFENIB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA AND CHILD’S B CIRRHOSIS
My Fellowship project was a Phase IB Clinical Trial of Sorafenib in Combination with Transarterial Chemoembolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma.
I did my Fellowship at the University of North Carolina at Chapel Hill.
My Fellowship was immensely important in my career. It provided me with specific research training and mentorship that wouldn’t have been possible as a junior staff oncologist. The clinical focus in GI and phase I clinical trials also allowed me to gain unique expertise.
I initially worked at the BC Cancer Agency Centre for the Southern Interior in Kelowna, and have recently relocated to the BC Cancer Agency Vancouver Centre.
DETERMINANTS OF GENOMIC RISK IN EARLY-STAGE BREAST CANCER
Determinants of genomic risk in early-stage breast cancer
Institut Jules Bordet, Breast International Group, Brussels, Belgium
Through my CAMO fellowship, I gained experience in oncology clinical research, developed a network of worldwide contacts in breast cancer medicine, and catalyzed an interest in early stage drug development and clinical genomics that has shaped my early career development.
Staff Medical Oncologist, Princess Margaret Cancer Centre, Associate Professor of Medicine, University of Toronto
A PHASE II STUDY OF SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCC) REFRACTORY TO PRIOR SUNITINIB OR BEVACIZUMAB THERAPY.
It was a phase II trial of sorafenib in kidney cancer. Interestingly, this trial never finished because the question was answered somewhere else later on in my Fellowship (ie we were scooped). However, it did allow me to embark on several other projects that have become very productive.
Cleveland Clinic Taussig Cancer Institute
The CAMO Fellowship was extremely important to me as I was able to meet and network with world famous people and build bridges for research in Canada. There are so many opportunities in the US ripe for the picking by a Canadian Fellow that can be brought back to Canada. Without the CAMO Fellowship I would have not had the chance to go to Cleveland and meet my current mentors. I would not have been able to build/chair the International mRCC Database Consortium without this Fellowship.
GU Tumor Group Chair, Tom Baker Cancer Center and University of Calgary, Calgary, Alberta
CHANGES IN BREAST TUMOR RECEPTOR STATUS WITH TIME-DOES PERFORMING A CONFIRMATORY BIOPSY AT THE TIME OF METASTIC RECURRENCE ALTER PATIENT MANAGEMENT?
My Fellowship project was (I believe) the first prospective study to assess change in tumour receptor status at the time of metastatic recurrence of breast cancer. We prospectively biopsied patients presenting with radiographic evidence of recurrence to determine if receptor status (ER/PR/Her2) changed with time. Previous studies in this area had relied on retrospective tumour banks which could have been subject to selection bias. This study received peer reviewed grant funding from CBCF as well, and I was given the opportunity to write and construct the grant application for this process. Publication from this project is below. Also was presented at ASCO and received an ASCO Merit award. Simmons CE, Miller N, Geddie W, Gianfelice D, Oldfield M, DranitsarisG, Clemons MJ. “Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?”. Ann Oncol. 2009 Sep:20(9):1499-504. Epub 2009 Mar 18. PubMed PMID: 19299408; PubMed Central PMCID: PMC2731014.
Princess Margaret Hospital in Toronto
Absolutely. My Fellowship gave me the opportunity to learn about the most effective ways of conducting research, gave me the opportunity to receive excellent mentorship from a variety of sources, and helped me to solidify my interests in research and teaching.
I am staff physician medical oncologist at the BC Cancer Agency in Vancouver. I sub-specialize in breast cancer and sarcoma. I also am the Course Director for clinical skills in the undergraduate medical program at UBC, and founder and chair of a not-for-profit organization (Women in Cancer/All in Cancer) which focuses in improving mentorship connections across the country. So in these ways, I am truly “paying it forward” – the investment CAMO made in me I am continuously grateful for!
Trinkaus M, Chin S, Wolfman W, Simmons CE, Clemons M. “Should urogenital atrophy in breast cancer survivors be treated with topical estrogens”? Oncologist 2008 Mar;13(3):222-31. Review. PubMed PMID 18378532.
Petrut B, Simmons CE, Broom R, Trinkaus M, Clemons M. “Pharmacotherapy of bone metastases in breast cancer patients”. Expert Opin Pharmacother. 2008 Apr;9(6):937-45. Review. PubMed PMID: 18377337.
Simmons CE, Broom RJ, Cole DE, Dranitsaris G, Clemons M. “Urinary N-telopeptide is a Rapid Predictor of Response and Palliative Benefit from Bisphosphonate Therapy in Metastatic Breast Cancer Patients”. Supportive Cancer Therapy, 2008 Sep 1;4(4):182-7. PubMed PMID: 18632515.
Amir E, Ooi W, Simmons CE, Khan H, Christaskis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. “Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies.”. Clinical Oncology, (R Coll Radio). 2008, Dec; 20 (10): 763-8.Epub 2008 Sept 27. PubMed PMID 18824337.
Chin S, Trinkaus M, Simmons CE, Bolivar R, Flynn C, Clemons M. “Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer”. Clinical Breast Cancer 2009 May; 9(2): 108-17. PubMed PMID: 19433392.
Broom RJ, Tang PA, Simmons CE, Bordeleau L, Mulligan AM, O’Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. “Changes in estrogen receptor, progesterone receptor, and Her2/neu status with time: discordance rates between primary and metastatic breast cancer.”. Anticancer Res. 2009 May: 29(5):1557-62. PubMed PMID: 19443366.
Amir E, Trinkaus M, Simmons CE, Dranitsaris G, Clemons MJ. “Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.”. Journal of Clinical Pathology. 2009 May; 62(5):474-6. PubMed PMID: 19398598.
Simmons CE, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DE. “Altered calcium metabolism in patient on long-term bisphosphonate therapy for metastatic breast cancer”. Anticancer Research 2009 Jul;29(7):2707-11. PubMed PMID: 19596950.
Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons CE, Ooi W, Cella D. “Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of cancer Therapy-Bone Pain”. J Pain Symptom Manage, 2009 Aug:38(2):244-57.
Simmons CE, Miller N, Geddie W, Gianfelice D, Oldfield M, DranitsarisG, Clemons MJ. “Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?”. Ann Oncol. 2009 Sep:20(9):1499-504. Epub 2009 Mar 18. PubMed PMID: 19299408; PubMed Central PMCID: PMC2731014.
Amir E, Simmons CE, (co-primary author), Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. “ A phase II trial exploring the effects of high-dose (10,000IU/day) vitamin D(3( in breast cancer patients with bone metastases. Cancer 2010 15;116(2):284-91. PubMed PMID: 19918922.
Trinkaus M, Simmons CE, Myers J, Dranatisaris G, Clemons M. “Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the non-trial setting”. Support Care Cancer: 2010 Feb:18(2):197-203. Epub 2009 May 8. PubMed PMID: 19424729.